期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 31, 期 4, 页码 405-409出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2018.09.009
关键词
Acute myeloid leukemia; AML; Core binding factor; Hematopoietic cell transplantation; HCT; Measurable residual disease; MFC; MRD; Multi-parameter flow cytometry; Next generation sequencing; NGS; NPM1; Reverse transcriptase polymerase chain reaction; RT-PCR
类别
资金
- NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018029] Funding Source: NIH RePORTER
- NCI NIH HHS [P01 CA018029, P30 CA015704] Funding Source: Medline
The persistence of measurable residual disease (MRD) following induction chemotherapy is the single most powerful prognostic factor available to clinicians treating patients with acute myeloid leukemia (AML). How to use this information to guide subsequent therapy is complex, and influenced by the category of AML being treated, the assays used to measure MRD, MRD levels and kinetics, and the spectrum of therapies available to the patient. In this literature-based review, each of these issues will be discussed, with a particular emphasis on the role of hematopoietic cell transplantation in the treatment of MRD-positive patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据